Neutron Capture Therapy
OwnerBipin Chandra Mujibhia Patelinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to immunoconjugates for use in neutron capture therapy, in particular Boron neutron capture therapy, for killing target cells such as tumours. The immunoconjugate of the invention comprises a monoclonal antibody having an affinity of at least 1011 l/mol and a cross-reactivity of less than 10%, and a neutron capture agent. More preferably, the affinity of the monoclonal antibody is at least 1012 l/mol.
Claims28
An immunoconjugate for targeting a neutron capture agent to a target cell comprising (i) a monoclonal antibody capable of binding to an antigen of the target cell with an affinity constant of at least 1011 l/mol and having a cross reactivity of less than 10%;
- and (ii) a neutron capture agent comprising a lipophilic carrier.
(canceled)
9-11. (canceled)
Dependencies are inferred from the claim text.